HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Frutaceuticals Shed Sugar To Shake Up Gummy Supplement Market

This article was originally published in The Rose Sheet

Executive Summary

Frutraceuticals are made with a technology that quickly evaporates moisture from heat-sensitive fruits to maintain raw material integrity without sugar, says marketer Frutarom Industries, which targets consumers seeking alternatives to vitamins in pill- and capsule-form but without sugar associated with gummies.

You may also be interested in...



In Gummy Vitamin Market, C&D Firm On ‘Long Game’ Over Short Gains

CEO Matthew Farrell says Church & Dwight will avoid the aggressive promotional trend sweeping the gummy vitamin market as it looks to stay competitive. Competitors’ promotions cut into its gummy sales and offset its other domestic consumer sales, which inched up 1.3%.

Church & Dwight Shapes Potential OTC Play On Gummy Format

The firm says sales of L’il Critters children’s and Vitafusion adults’ gummy vitamin lines increased more than 7% in its fiscal 2015 third quarter from the year-ago period as production and distribution began recovering from disruptions that restrained sales in the previous quarter.

Supplement Demographic Expansion Drives Emerging Category Growth

Consumers’ reasons for using supplements and the delivery formats they prefer are growing. Emerging growth categories include natural supplements and those aimed at heart health, diabetes and muscle-retention.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121234

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel